IP
IndiaPulse

SHARDACROP

Micro Cap

Sharda Cropchem Limited

Industrials

Sharda Cropchem is an Intellectual Property (IP) driven company engaged in marketing and distribution of wide range of formulations and generic active ingredients. It operates on an asset-light model, outsourcing manufacturing, and focuses on registrations, marketing, and distribution across 80+ countries.

₹885.1
+17.15 · +1.98%
Quote09 Jun, 10:02 am
Fundamentals08 Jun 2026 · screener
Score08 Jun, 11:00 pm · v4.2-nightly
Tags02 May 2026
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Strong fundamentals, management trust is supportive, price trend is neutral, and recent execution is consistent.

Suggested next step
Candidate for deeper work
Valuation is strong. Wait for stronger Trust evidence before treating this as high conviction.
U-Score
DEEP VALUE
90

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
High Trust
86

low confidence · 0/0 claims checked

Technical
Neutral
48

Timing lens: price trend and sector relative strength.

Result consistency
stable
79

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 31 Mar 2026

Excellent · 90/100

Rev +13% YoY · PAT +56% YoY · margin expansion · +60% QoQ · operating leverage

Filed 13 May 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹2,065 Cr+12.9%+60.2%
EBITDA₹487 Cr+60.7%+102.1%
Operating margin24.0%+700 bps+500 bps
PAT₹319 Cr+56.4%+120.0%
PAT margin15.4%+430 bps+420 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business and thesis

Where growth can come from, and what can break the case

Thesis intactReviewed 2026-06-03T13:54:01.772Z
Management commentary snapshot

SHARDACROP reported strong Q4 FY26 and full-year FY26 results. Q4 revenue grew 13% YoY, with Agrochemicals up 14%. Full-year revenue increased 22% YoY, driven by 13.3% volume growth in Agrochemicals. Gross Margins improved significantly, leading to a 75% YoY EBITDA jump in Q4 and 69% for FY26.

The company delivered robust financial performance in FY26, marked by strong revenue growth, significant margin expansion, and improved profitability. The asset-light model and focus on registrations appear to be yielding results, particularly in the Agrochemical segment. Management expects current gross margins to sustain.

Current business mix

FY26 Agrochemical Revenue by Product

Latest issuer-disclosed distribution across 3 reported categories.

Businessmix
Herbicides51.0%
Fungicides28.0%
Insecticides21.0%
Growth engines

Forward Integration

Building sales force to adopt 'factory to farmer' approach in NAFTA, Europe, LATAM, and RoW.

Expand & Strengthen Distribution

Expanding geographical reach using existing library of dossiers and penetrating new markets.

Continual Investment in Registrations

Identifying generic molecules going off patent and investing in preparing dossiers and seeking registrations.

Growing Global Population

Global population projected to rise from 7.6 Bn in 2025 to 8.6 Bn by 2030, placing pressure on food systems.

Capacity and execution

CAPEX Incurred

Rs. 505 Cr. CAPEX incurred in FY26.

Tailwinds

Growing Population

Global population growth fuels demand for increased food and protein production, driving demand for crop protection.

Fewer Arable Acres

Arable land expected to decrease, necessitating products that maximize farmer yields.

Management accountability

What management said, and what results must prove

Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.

Analyst reading lens
Compare BOTH

Q4 results provide insight into recent sequential momentum and product/region mix shifts, while full-year (FY26) results offer a comprehensive view of annual performance and the impact of strategic initiatives, which is crucial for a potentially seasonal agrochemical business.

Sector KPIs management disclosed

Revenue from Operations

Q4 FY26: 2,064.9 Cr (+13% YoY); FY26: 5,267.6 Cr (+22% YoY).

Agrochemical Volumes Growth

Q4 FY26: +4.5% YoY; FY26: +13.3% YoY.

Gross Margin

Q4 FY26: 37.3% (vs 29.8% Q4 FY25); FY26: 35.9% (vs 29.9% FY25).

EBITDA Margin

Q4 FY26: 24.8% (vs 16.0% Q4 FY25); FY26: 19.7% (vs 14.2% FY25).

Management forward view

Gross Margins Outlook

Gross Margins are expected to remain at current levels in FY27.

Strategic Focus

Leverage market presence, expand geographical reach, and invest in product registrations.

Operational Efficiency

Accelerated focus on revenue generating investments, margin improvements, and better cost management.

Thesis monitor

Numbers and claims to verify in the next filings

CheckpointCurrent evidenceWhat to verify next
Gross Margin35.9% (FY26)Sustenance of improved gross margins in FY27 as guided by management.
Agrochemical Volume Growth13.3% (FY26)Continued volume growth across regions, particularly Europe and LATAM, which were key contributors.
Working Capital Days98 days (Mar-26)Further reduction or efficient management of working capital to maintain balance sheet strength.
New Registrations1,004 applications pendingSuccessful conversion of pending applications into new product registrations to fuel future growth.

Verification checkpoints are IndiaPulse research interpretation, not investment advice.

Technical timing lens

Trend score and candlestick chart

48Neutral

label neutral

Stock trend: 46
Sector RS: 51
Sector 3M: +0.4% vs Nifty +0.1%

Technical chart

SHARDACROPweekly · 1Y+9.2%
Latest close ₹885.30 on 2026-06-09
Bar
+1.2%
RSI
45
MACD hist
-8.34
52W pos
24%
Hover for OHLC, volume, and indicators. Use range buttons above the chart to zoom.
₹732₹880₹1.0k₹1.2k₹1.3k52H52L2025-062025-092025-122026-03Vol2025-062025-102026-012026-052026-06
Up bar
Down bar
Volume
Result date
SMA 50
RSI(14)

Technical trend read

Neutral

Trend is undirectional — long-term trend unclear. RSI 45.

  • SMA20 roughly flat — short-term momentum stalled.
  • RSI(14) at 45 — sideways, no extreme reading.
  • MACD below signal but histogram contracting — bearish momentum easing.
  • 32% off 52W high · 17% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Deep research

Valuation, score drivers, trust methodology, financials, and peers

Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.

90U-SCORE
Top Setup

Fundamental score breakdown

DEEP VALUE
Valuation22/30
Growth22/25
Quality20/20
Balance Sheet14/15
Cash Flow7/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
90

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

90/100 · DEEP VALUE

Positive drivers

  • Piotroski is strong at 8/9.
  • Fair-value margin of safety is positive at 73.9%.
  • Quality contributes 20/20 to the score.

Main drags

  • Cash flow is weaker at 7/10; verify the latest quarterly trend.
  • Valuation is weaker at 22/30; verify the latest quarterly trend.
  • Growth is weaker at 22/25; verify the latest quarterly trend.
Sector valuation model

Cyclical valuation: normalized earnings, not just trailing PE

Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.

Cyclical normalized
Primary lens
Mid-cycle PE/EV/EBITDA using multi-year average margins or earnings.
Secondary checks
Current margin versus 5-year average, balance sheet strength, commodity cycle.
Main risk check
A low trailing PE may mean peak-cycle earnings, not true cheapness.
PE
11.5
PB
2.5
EV/EBITDA
5.6
ROE
24.2%
ROCE
30.4%
FCF Yield
1.8%
Debt/Equity
0.0
MoS
+73.9%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 08 Jun 2026
v4.2-nightly
Final score
90
Previous: 90
Verdict
DEEP VALUE
Previous: DEEP VALUE
Margin of safety
+73.9%
Previous: +74.5%

Score history

12 stored score snapshots. Latest stored move: +0 points.

08 Jun 2026
v4.2-nightly
90
89
89
89
89
89
89
89
90
90
90
90

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Trust Score
86High Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

High Trust: Claim history is still being built. It ranks around the 99th percentile of the scored universe and 99th percentile within Industrials. No major sub-score weakness stands out.

High Trust Lite: Promoter holding is 74.8%.

Computed 22 May 2026
trust-lite-v1
0 docs indexed · 0 concall links
Score band
High Trust

Management behaviour ranks as unusually reliable. Still verify valuation and cycle risk.

Relative rank
99th percentile

overall median 67 · Industrials: 99th pctile, median 68 · Micro: 98th pctile, median 71

Evidence depth
Financial-only

0 documents indexed, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

High Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
79
strong · quarterly consistency

Trust positives

  • Promoter holding is 74.8%.
  • Promoter pledge is zero.
  • FCF yield is positive at 1.8%.
  • 9 years of positive FCF.

Trust risks

  • No major Trust Lite risk flags.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Intrinsic value

Graham Number
₹768.72
-15.1% MoS
DCF Fair PE
45.0
DCF Fair Value
₹3,396.15
+73.9% MoS
PEG
0.45

Fundamentals

Valuation

P/E
11.50
P/B
2.49
EV/EBITDA
5.59
Market Cap
7827.00Cr

Profitability

ROE
24.20%
ROCE
30.40%
ROA
11.78%
Dividend Y
1.04%

Growth (CAGR)

Revenue 5Y
17.00%
EPS 5Y
25.00%
Revenue 3Y
9.00%
EPS 3Y
27.00%

Balance Sheet

Debt/Equity
0.00
Interest Coverage
538.00×
Altman Z
4.24
Book Value
348.00

Cash Flow

FCF Yield
1.83%
FCF Positive Y
9/5
OCF
656.00 Cr
EPS TTM
75.47

Shareholding

Promoter Hold
74.82%
Promoter Pledge
0.00%
Momentum 52W
21%

Financial History

Updated 9/6/2026

Revenue

₹ Cr
Latest: 4,631+26.5% vs prev
04631Mar 2016: 934Mar 2017: 1,129Mar 2018: 1,470Mar 2019: 1,604Mar 2020: 1,616Mar 2021: 2,946Mar 2022: 3,313Mar 2023: 2,603Mar 2024: 3,661Mar 2025: 4,631FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

Net Profit

₹ Cr
Latest: 274+100.0% vs prev
0325.0Mar 2016: 172Mar 2017: 189Mar 2018: 193Mar 2019: 144Mar 2020: 192Mar 2021: 210Mar 2022: 283Mar 2023: 325Mar 2024: 137Mar 2025: 274FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

Return on Equity

%
Latest: 304+6350.0% vs prev
0304.4Mar 2016: 23.3%Mar 2017: 21.2%Mar 2018: 18.1%Mar 2019: 12.3%Mar 2020: 14.7%Mar 2021: 14.0%Mar 2022: 16.4%Mar 2023: 13.9%Mar 2024: 4.7%Mar 2025: 304%FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.